>>It seems to me what Ligand needs most now is a revenue stream to begin offsetting the increased cash burn that will evolve as ALRI becomes history. If I were Robinson, I'd be looking for a generic house that addressed at least some of the key markets that I expected to address withmy current stable of compounds. It seems to me that the last thing Ligand needs right now is another compound to develop.<<
Remember Ted, we don't know much about this protein or perhaps, the technology behind it. Needs no development for its CTCL indication, since P3s are due to end soon. Other indications would need development, but there may be some synergies here we are unaware of. In any case, its all rampant speculation. Although one would think if something special were available here, the company would not be in such dire straights.
Problem is that LGND has very little cash to spare for acquisitions and I don't see how they could afford the kind of company you describe, especially with their burn rate set to increase. Of course, their acquisition needn't necessarily have anything to do with the LLY drug they select. They should select their drug carefully, tho, since it will cost them a pretty penny. If they don't exercise the option, they will gain a pretty penny. So this choice is worth about 30M or more. |
